Factors underlying reduced aerobic capacity in Huntington disease
Objective: Examine factors underlying aerobic capacity in prodromal and manifest Huntington disease (HD) and matched controls Background: HD results in motor impairments, weight loss, muscle…The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: Design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients (DYSCOVER Study)
Objective: The DYSCOVER study will be the first interventional, randomized study to evaluate the comparative effectiveness of levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment…Availability of Parkinson’s disease medicines in Ghana: a national survey
Objective: To determine the affordability, availability, geographic distribution and financing options of Parkinson’s disease (PD) medication in Ghana. Background: In sub-Saharan Africa, patients with PD…Safety of Iron Chelation in Patients with Brain Iron Overload
Objective: To assess the safety of iron chelation in the treatment of regional brain iron overload. Background: Excess brain iron is evident in neurodegenerative diseases…Changes to Speech Production after SpeechVive Treatment in Individuals with Parkinson’s Disease
Objective: The purpose of the present study was to assess the effects of a device-driven treatment (SpeechVive) on respiratory and laryngeal function after 8 weeks…Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study
Objective: To evaluate the long-term safety and efficacy of apomorphine infusion (APO) in PD patients with motor fluctuations despite optimised oral therapy. Background: The randomised,…Risk Thresholds of Levodopa Dose for Dyskinesia in Chinese Patients with Parkinson’s Disease: A Pilot Study
Objective: The objective of this study was to investigate the thresholds of levodopa dose to reduce the risk for dyskinesia in a Chinese PD population.…Smartphone software for home monitoring of motor symptoms in Parkinson’s disease – The CloudUPDRS Smartphone Software in Parkinson’s (CUSSP) study
Objective: To determine the validity of smartphone software for objective monitoring of motor symptoms in patients with Parkinson’s disease (PD). Background: Although the MDS-Unified Parkinson’s…Parotitis as Adverse Event Following BoNT Injections for Sialorrhea
Objective: Review potential adverse events of parotitis with botulinum toxin injections for sialorrhea. Background: Sialorrhea is a common non-motor symptom of Parkinson’s disease. Botulinum toxin…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the patients’ and clinicians’ perception of PD symptoms improvement [as assessed by…
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 217
- Next Page »